{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:30:46Z","timestamp":1770179446864,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"DOI":"10.1007\/s00270-025-04258-6","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T17:02:13Z","timestamp":1762534933000},"page":"324-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intra-arterial Hepatic 177Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9614-0723","authenticated-orcid":false,"given":"Ruben K.","family":"Fakkert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur J. A. T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"de Keizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rutger C. G.","family":"Bruijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl P.","family":"Bruijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex J.","family":"Poot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten L. J.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marnix G. E. H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"12","key":"4258_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"issue":"12","key":"4258_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/RLU.0000000000003307","volume":"45","author":"S Satapathy","year":"2020","unstructured":"Satapathy S, Mittal BR, Sood A. Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate cancer treated with 177Lu-labeled prostate-specific membrane antigen radioligand therapy: a systematic review and meta-analysis. Clin Nucl Med. 2020;45(12):935\u201342. https:\/\/doi.org\/10.1097\/RLU.0000000000003307.","journal-title":"Clin Nucl Med"},{"key":"4258_CR3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00259-023-06581-x","volume":"51","author":"CM Deroose","year":"2024","unstructured":"Deroose CM. The LUTIA trial: a small step for PRRT, a giant leap for intra-arterial radionuclide therapy trial methodology. Eur J Nucl Med Mol Imaging. 2024;51:1133\u20135. https:\/\/doi.org\/10.1007\/s00259-023-06581-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4258_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3888-0","volume":"21","author":"SC Ebbers","year":"2020","unstructured":"Ebbers SC, Braat AJAT, Moelker A, Stokkel MPM, Lam MGEH, Barentsz MW. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials. 2020;21:141. https:\/\/doi.org\/10.1186\/s13063-019-3888-0.","journal-title":"Trials"},{"key":"4258_CR5","unstructured":"World Health Organization. International atomic agency (IAEA)\/WHO guidelines on good manufacturing practices for radiopharmaceutical products. WHO Drug Information, 2019;33(3), 395\u2013409."},{"issue":"6","key":"4258_CR6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2967\/jnumed.120.252494","volume":"62","author":"SC Ebbers","year":"2021","unstructured":"Ebbers SC, Barentsz MW, de Keizer B, Krijger GC, Lam MGEH, Braat AJAT. A rapid and safe infusion protocol for 177Lu peptide receptor radionuclide therapy. J Nucl Med. 2021;62(6):816\u201322. https:\/\/doi.org\/10.2967\/jnumed.120.252494.","journal-title":"J Nucl Med"},{"key":"4258_CR7","unstructured":"Nederlandse Vereniging voor Nucleaire Geneeskunde. Blootstelling van derden bij therapie met 177Lu. In Werken met therapeutische doses radionucliden. Richtlijnendatabase. 2021"},{"key":"4258_CR8","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) Version 5.0. 2017"},{"issue":"12","key":"4258_CR9","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2967\/jnumed.117.193581","volume":"58","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, et al. Initial experience with volumetric 68Ga-PSMA I&T PET\/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017;58(12):1962\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.193581.","journal-title":"J Nucl Med"},{"issue":"61","key":"4258_CR10","doi-asserted-by":"publisher","first-page":"103108","DOI":"10.18632\/oncotarget.21600","volume":"8","author":"H Ahmadzadehfar","year":"2017","unstructured":"Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017;8(61):103108\u201316. https:\/\/doi.org\/10.18632\/oncotarget.21600.","journal-title":"Oncotarget"},{"issue":"1","key":"4258_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00259-020-04828-5","volume":"48","author":"F Khreish","year":"2021","unstructured":"Khreish F, Kochems N, Rosar F, Sabet A, Ries M, Maus S, et al. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2021;48(1):103\u201312. https:\/\/doi.org\/10.1007\/s00259-020-04828-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4258_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF00463556","volume":"239","author":"J von Scheel","year":"1984","unstructured":"von Scheel J, Golde G. Pharmacokinetics of intra-arterial tumour therapy. Arch Otorhinolaryngol. 1984;239:153\u201361. https:\/\/doi.org\/10.1007\/BF00463556.","journal-title":"Arch Otorhinolaryngol"},{"issue":"1","key":"4258_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1055\/s-0038-1676300","volume":"3","author":"SC Ebbers","year":"2019","unstructured":"Ebbers SC, Barentsz MW, Braat AJ, Lam MG. Intra-arterial peptide receptor radionuclide therapy for neuroendocrine tumor liver metastases. Dig Dis Interv. 2019;3(1):81\u201390. https:\/\/doi.org\/10.1055\/s-0038-1676300.","journal-title":"Dig Dis Interv"},{"issue":"1","key":"4258_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2967\/jnumed.120.245068","volume":"62","author":"LD Jim\u00e9nez-Franco","year":"2021","unstructured":"Jim\u00e9nez-Franco LD, Glatting G, Prasad V, Weber WA, Beer AJ, Kletting P. Effect of tumor perfusion and receptor density on tumor control probability in 177Lu-DOTATATE therapy: an in silico analysis for standard and optimized treatment. J Nucl Med. 2021;62(1):92\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.245068.","journal-title":"J Nucl Med"},{"issue":"9","key":"4258_CR15","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jvir.2022.05.023","volume":"33","author":"A Bibok","year":"2022","unstructured":"Bibok A, Kis B, Frakes J, Hoffe S, et al. Yttrium-90 radioembolization for liver-dominant metastatic prostate cancer: a case series. J Vasc Interv Radiol. 2022;33(9):1061\u20135. https:\/\/doi.org\/10.1016\/j.jvir.2022.05.023.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"4258_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2967\/jnumed.119.233429","volume":"61","author":"R Seifert","year":"2020","unstructured":"Seifert R, Kessel K, Boegemann M, K\u00f6hler M, Roll W, Stegger L, et al. Additional local therapy for liver metastases in patients with metastatic castration-resistant prostate cancer receiving systemic PSMA-targeted therapy. J Nucl Med. 2020;61(5):723\u20138. https:\/\/doi.org\/10.2967\/jnumed.119.233429.","journal-title":"J Nucl Med"},{"key":"4258_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00259-023-06467-y","volume":"51","author":"SC Ebbers","year":"2024","unstructured":"Ebbers SC, Barentsz MW, de Vries-Huizing DMV, et al. Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: An in-patient randomised controlled trial (LUTIA). Eur J Nucl Med Mol Imaging. 2024;51:1121\u20132113.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"4258_CR18","doi-asserted-by":"publisher","first-page":"20041","DOI":"10.1038\/s41598-019-56603-8","volume":"9","author":"NJ Begum","year":"2019","unstructured":"Begum NJ, Glatting G, Wester HJ, Eiber M, Beer AJ, Kletting P. The effect of ligand amount, affinity, and internalization on PSMA-targeted imaging and therapy: a simulation study using a PBPK model. Sci Rep. 2019;9(1):20041. https:\/\/doi.org\/10.1038\/s41598-019-56603-8.","journal-title":"Sci Rep"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04258-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-025-04258-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04258-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:04:27Z","timestamp":1770131067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-025-04258-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4258"],"URL":"https:\/\/doi.org\/10.1007\/s00270-025-04258-6","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AB is a consultant for Terumo, Boston Scientific, Telix Pharmaceuticals, and GE Healthcare; he receives research support from Boston Scientific, Terumo, Telix Pharmaceuticals, Siemens Healthineers, and Ariceum Therapeutics. CB has received a speaker honorarium from Novartis, Johnson & Johnson, and Astellas. ML is a consultant for Terumo, Boston Scientific, OncoSil, Becton and Dickinson, and Novartis; he receives research support from Terumo, Boston Scientific, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This study has obtained IRB approval from (Medical Ethics Review Committee of the UMC Utrecht in the Netherlands (24U-0056)), and the need for informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"For this type of study, consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}